LenioBio Secures €3.7 Million EU4Health Funding for ALiCE® Project to Revolutionize Protein-Based Drug Production
LenioBio Secures EU4Health Funding: A Leap Towards Advanced Medicine Production
In a significant development in the field of biopharmaceuticals, LenioBio GmbH has received a grant amounting to €3.7 million from the European Health and Digital Executive Agency (HaDEA). This funding is part of the EU4Health initiative, which aims to enhance the availability and affordability of essential medications across Europe. The grant was officially awarded on July 1, 2025, and will continue until the end of 2027.
What is the ALiCE® Project?
The focus of the funding is the further development of the ALiCE® platform, which stands for ‘A Cell-free protein production system’, designed to efficiently produce complex proteins crucial for various medical applications. By utilizing a cell-free system, ALiCE® allows for a smoother scale-up from research to production, ensuring that pharmaceutical manufacturers can produce bespoke medicines without the limitations of living cells.
The main objectives of the project are:
1. Scaling the ALiCE® Production: This includes optimizing yield processes, increasing batch sizes, and transitioning to continuous manufacturing techniques to enhance production speed and efficiency.
2. Expanding Capabilities: LenioBio aims to broaden the functional capabilities of ALiCE® specifically for targeted classes of protein medicines. This includes developing technologies for vaccines, multispecific antibodies, and growth factors, all while demonstrating modular protein production methodologies on a larger scale.
3. Establishing Quality Standards: Implementing Good Manufacturing Practice (GMP) quality standards for lysate production by defining analytical qualifications, quality systems, and submission packages for regulatory approvals.
A Vision for the Future
André Goerke, the CEO of LenioBio, expressed excitement over this new grant, stating, “This grant is another critical milestone for LenioBio. It enables us to scale our platform and broaden its application for drug manufacturing, positioning us to offer a future-proof solution for flexible production of novel, complex proteins.”
The project has also received the prestigious STEP Seal from the European Commission, acknowledging its strategic importance for Europe’s technological and health sovereignty. This seal is a clear signal to stakeholders about the project's potential impact and relevance.
The Role of EU4Health
The EU4Health program was launched in response to the COVID-19 pandemic, aiming not only to improve emergency readiness but also to strengthen the resilience of Europe's health systems. It provides funding for initiatives that improve access to medical products, enhance cross-border health security, and promote innovations in healthcare. The ALiCE® project fits perfectly within this framework, championing innovative production methods that contribute to sustainable, efficient, and environmentally friendly drug production.
About LenioBio
Founded in September 2016, LenioBio GmbH is based in Düsseldorf, Germany, with production labs in Aachen. The company is dedicated to advancing protein expression technologies that transcend traditional cellular limitations in drug discovery and production.
For more insights on LenioBio and ongoing developments, you can visit their official website at www.leniobio.com and follow them on LinkedIn.
Conclusion
With the EU4Health funding, LenioBio's ALiCE® project represents a pivotal step towards innovative healthcare solutions in Europe. By leveraging cutting-edge technology to produce critical medicinal proteins rapidly and cost-effectively, LenioBio is set to play an essential role in the future landscape of biopharmaceutical manufacturing.
Topics Health）
【About Using Articles】
You can freely use the title and article content by linking to the page where the article is posted.
※ Images cannot be used.
【About Links】
Links are free to use.